Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael Choi

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0820
    CA La Jolla 92093
    Phone858-534-1765
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Seymour JF, Ma S, Brander DM, Choi M, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Jan 12. PMID: 28089635.
        View in: PubMed
      2. Choi M, Kipps TJ. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 Sep 15; 30(9). PMID: 27633418.
        View in: PubMed
      3. Choi M, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016 Mar; 29(1):40-53. PMID: 27742071.
        View in: PubMed
      4. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 Aug; 15(8):1781-91. PMID: 27413114.
        View in: PubMed
      5. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi M, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2015 Dec 4. PMID: 26646452.
        View in: PubMed
      6. Choi M, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. PMID: 26297272.
        View in: PubMed
      7. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi M, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 May 1. PMID: 25934707.
        View in: PubMed
      8. Stout EP, Choi M, Castro JE, Molinski TF. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J Med Chem. 2014 Jun 26; 57(12):5085-93. PMID: 24673739.
        View in: PubMed
      9. Choi M, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. PMID: 23006944.
        View in: PubMed
      10. Lu D, Choi M, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9; 108(32):13253-7. PMID: 21788521.
        View in: PubMed